All in favor say ‘eye’
Executive Summary
Bausch & Lomb's Optura (besifloxacin ophthalmic suspension) receives unanimous support Dec. 5 for treatment of bacterial conjunctivitis. Members of FDA's Dermatologic and Ophthalmic Drugs Advisory Committee added no hesitations or qualifications to their 9-0 vote that besifloxacin's benefits outweigh its risks, agreeing with FDA's conclusions that the sponsor conducted three adequate and well-controlled trials supporting the drug's efficacy